The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
What Trump’s New Drug Pricing Deal Means for People With Obesity
Written by
in
Drugs (Pharmaceuticals), Eli Lilly and Company, Food and Drug Administration, GLP-1 RAs (Drug), Health Insurance and Managed Care, Medicaid, Medicare, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry, Trump, Donald J, United States Politics and Government